XYLOCAINE INJECTION Rx
Generic Name and Formulations:
Lidocaine HCl 5mg/mL, 10mg/mL, 20mg/mL; soln; contains methylparaben.
Fresenius Kabi USA
Indications for XYLOCAINE INJECTION:
Local or regional anesthesia for infiltration and nerve block (see full labeling).
See full labeling for recommended dosages based on procedures. Epidural anesthesia: administer test dose first; monitor for CNS or cardiovascular toxicity. For all procedures: Max total dose: 4.5mg/kg not to exceed 300mg; epidural or caudal anesthesia should not be administered at intervals <90 minutes. Paracervical block: max 200mg total per 90 minute period. Elderly, debilitated, acutely ill (eg, cardiac or liver disease): reduce dose.
<3yrs: individualize based on weight and age. >3yrs: usual max dose: 1.5–2mg/lb. See full labeling for dosages specific to procedures.
To be administered under the supervision of experienced clinicians. Have intubation, artificial respiration, oxygen therapy and reversal agents available. Risk of methemoglobinemia (esp. in G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants <6 months of age, concurrent exposure to oxidizing agents or metabolites); monitor. Intra-articular infusions: not recommended. Avoid intravascular inj. Avoid methylparaben with spinal or epidural anesthesia. Monitor cardiovascular and respiratory vital signs. Severe shock. Heart block. Neurological disease. Spinal deformities. Septicemia. Severe hypertension. Hepatic disease. Impaired cardiovascular function. Malignant hyperthermia. Head and neck administration. Labor & delivery: see full labeling. Pregnancy (Cat.B). Nursing mothers.
Increased risk of methemoglobinemia when concurrently exposed to nitrates/nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, others. Additive effects with other products containing local anesthetics.
CNS effects (eg, lightheadedness, confusion), cardiovascular effects (eg, bradycardia, hypotension, cardiovascular collpase), hypersensitivity reactions, headache, backache, nausea, increased creatinine phosphokinase.
Multi-dose vial (10mL, 20mL, 50mL)—25; MPF plastic ampules (10mL, 20mL)—5; MPF single-dose vial (2mL, 5mL, 50mL)—25; MPF single-dose vial (30mL)—5, 25
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Steps to Facilitate Rapid Reperfusion to Improve Poststroke Outcomes
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes